儿童抽动障碍药物治疗研究进展  

Advances of medicated management for tic disorder in children

作　　者：王华[1] Wang Hua(Department of Child Neurology,Shengjing Hospital,China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学盛京医院小儿神经内科,沈阳110004

出　　处：《中华实用儿科临床杂志》2024年第4期271-275,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：近年来由于儿童抽动障碍(TD)发病年龄更小、治愈率降低及难治性病例增多,儿童TD的治疗愈发引起人们的关注。现就TD的药物治疗进展,包括α2肾上腺素能激动剂、多巴胺D受体阻滞剂、典型和非典型抗精神病类药物、抗癫痫发作药物、肉毒杆菌毒素A,以及持续至成年期的儿童TD的治疗进行重点介绍,旨在强调儿童TD的正规治疗、足疗程治疗以及个体化治疗的理念。In recent years,more attention has been paid to the treatment of tic disorder(TD)in children owing to a decrease in onset of age and cure rate and an increase in refractory cases.The present article reviews advances in drug therapies for TD,includingα2-adrenergic receptors,dopamine receptor D blockers,typical and atypical antipsychotic drugs,antiepileptic drugs,and botulinum toxin type A,as well as the sustainable treatment up to adulthood.It also highlights the regular treatment,full-course treatment,and individualized treatment for TD in children.

关 键 词：抽动障碍 儿童 药物治疗 

分 类 号：R749.94[医药卫生—神经病学与精神病学]